Abstract:The etiology of Parkinson's disease (PD) has long been thought to involve both genetic and environmental factors. There exists a common theme across the etiological spectrum of PD, where these factors have the ability to cause nigrostriatal dopaminergic (DA) cell death by interfering with mitochondrial function, inducing oxidative stress and altering proteosomal function. The protein α-synuclein (α-syn) that forms characteristic inclusions termed Lewy bodies in familial or sporadic forms of PD is thought to play a central role in PD pathology. Due to the absence of an effective treatment for PD progression, it is necessary to identify various genetic or environmental modifiers to advance drug discovery and therapeutic development. Animal models like Caenorhabditis elegans are often preferable for experimental research in the study of neurodegenerative diseases as this microscopic nematode combines ease of handling and manipulation, high reproductive rates and facilitation of large-scale experiments. Reminiscent of the situation observed in PD patients, expression of PD associated genetic factors or exposure to environmental neurotoxicants causes various phenotypes in worms such as, robust cell-type specific DA neurodegeneration, occurrence of protein misfolding/aggregates and associated behavioral/locomotion defects. These parameters can be analyzed and quantified, thus rendering the nematode model useful for uncovering mechanistic aspects of PD pathology, including genetic or environmental factors, or interactions affecting neurodegeneration. Using C. elegans as an environmental model system, we elucidated the toxicological effects and mechanism for two different classes of bacterial metabolites in causing neurodegeneration/PD related phenotypes. We demonstrated that a previously identified bacterial neurotoxic metabolite produced by Streptomyces spp. caused neuronal cell death as a result of mitochondrial dysfunction and oxidative stress in worms. Interestingly, the neurotoxic effect of this metabolite was enhanced in the presence of α-syn, indicating a functional association. Our study highlights the toxic phenotypes of another group of bacterial products, phenazines, which enhanced α-syn-induced protein aggregation and neurodegeneration in worms. We also determined that phenazine compounds upregulated cellular stress responses in the ER and mitochondria, thus representing a potential PD-related environmental risk factor. Finally, using C. elegans as a genetic model system for PD, we have reported a previously uncharacterized neuroprotective gene product, RTCB-1 that has the ability to regulate xbp-1 mRNA splicing in the unfolded protein response pathway (UPR). Using cell-specific RNA interference (RNAi), we have shown that RTCB-1 rescues α-syninduced DA neurodegeneration by regulating XBP-1 signaling and activating downstream chaperones in the UPR; thus mitigating the toxic effects caused by accumulation of unwanted proteins. The combined outcomes of this research represent mechanistic advances in our understanding of factors, both heritable and environmental, that exert an influence on neurodegeneration. The evolutionarily conserved pathways and functional targets revealed through this work highlight the expeditious manner by which C. elegans can be exploited to accelerate the path toward attenuating devastating diseases like PD. Ms. Arpita Ray University of Alabama Wednesday, May 21, 2014 10:00 AM SEC RM 2436

A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic Caenorhabditis elegans

Neuroprotection in C. Elegans Parkinsons Disease Models: Discovering Therapeutic Insights via RNAi and Small Molecule High Throughput Screening

Identification and mechanistic analyses of genetic and environmental risk factors associated with Parkinson's disease using a Caenorhabditis elegans model

Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy

High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model

Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a C. elegans Model of LRRK2-Induced Parkinson's Disease

Anti-α-synuclein Toxicity and Anti-neurodegenerative Role of Chrysin in Transgenic Caenorhabditis Elegans Models of Parkinson's Disease.

Multiple checkpoints of protein clearance machinery are modulated by a common microRNA, miR-4813-3p, through its putative target genes: Studies employing transgenic C. elegans model

Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease

Functional implications of NHR-210 enrichment in C. elegans cephalic sheath glia: insights into metabolic and mitochondrial disruptions in Parkinson's disease models

Novel Molecular Targets and Mechanisms for Neuroprotective Modulation in Neurodegenerative Disorders

Delaying aging is neuroprotective in Parkinson’s disease: a genetic analysis in C. elegans models

Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies

Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways

Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications

Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson’s Disease

Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression

Ribose-cysteine and levodopa abrogate Parkinsonism via the regulation of neurochemical and redox activities in alpha-synuclein transgenic Drosophila melanogaster models

PIWI-interacting RNA Expression Regulates Pathogenesis in a Caenorhabditis Elegans Model of Lewy Body Disease

Alpha-Synuclein Aggregation in Parkinson's Disease

Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of Α-Synuclein Gene in a Mouse Model of Parkinson's Disease.